Genentech licenses anti-cancer compounds from ImmunoGen
‘Genentech has purchased rights to use anti-cancer compounds from ImmunoGen, a biopharmaceutical company focused on developing targeted anti-cancer treatments.
Under the agreement Genentech will use the Immunogen compounds in combination with its own therapeutic antibodies, on particular undisclosed targets. Shares in ImmunoGen climbed almost 10% in the wake of the news.
ImmunoGen will receive a $1 million license payment, and is entitled to receive milestone payments, and royalties on the sales of any resulting products. Genentech is responsible for the development, manufacturing, and marketing of any products resulting from the license. This is the third such license which Genentech has acquired from ImmunoGen.’
Read more at Genentech licenses anti-cancer compounds from ImmunoGen
Recent Entries
- Sigma Pharmaceuticals year profit rises 27 pct
- South African citizens cheap drug guinea pigs
- Two drugs test victims face a year in coma
- Can drug companies improve their reputation?
- Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
- Pfizer’s Forecast Disappoints
- Pharmaceutical RFID Adoption Stalls
- Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
- GlaxoSmithKline unveils best results since merger
- Pfizer Sues Teva, Sandoz Over Zithromax